|
Gene: ATP5F1C |
Gene summary for ATP5F1C |
Gene summary. |
Gene information | Species | Human | Gene symbol | ATP5F1C | Gene ID | 509 |
Gene name | ATP synthase F1 subunit gamma | |
Gene Alias | ATP5C | |
Cytomap | 10p14 | |
Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | P36542 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
509 | ATP5F1C | GSM4909281 | Human | Breast | IDC | 5.14e-16 | 5.46e-01 | 0.21 |
509 | ATP5F1C | GSM4909282 | Human | Breast | IDC | 2.09e-07 | 3.39e-01 | -0.0288 |
509 | ATP5F1C | GSM4909285 | Human | Breast | IDC | 1.30e-78 | 1.12e+00 | 0.21 |
509 | ATP5F1C | GSM4909286 | Human | Breast | IDC | 5.43e-17 | 4.19e-01 | 0.1081 |
509 | ATP5F1C | GSM4909287 | Human | Breast | IDC | 9.30e-05 | 3.75e-01 | 0.2057 |
509 | ATP5F1C | GSM4909290 | Human | Breast | IDC | 4.42e-02 | 2.73e-01 | 0.2096 |
509 | ATP5F1C | GSM4909293 | Human | Breast | IDC | 6.65e-06 | 1.72e-01 | 0.1581 |
509 | ATP5F1C | GSM4909296 | Human | Breast | IDC | 1.77e-02 | 1.98e-01 | 0.1524 |
509 | ATP5F1C | GSM4909297 | Human | Breast | IDC | 1.23e-02 | 7.58e-02 | 0.1517 |
509 | ATP5F1C | GSM4909298 | Human | Breast | IDC | 9.92e-03 | 8.18e-02 | 0.1551 |
509 | ATP5F1C | GSM4909305 | Human | Breast | IDC | 1.97e-07 | 3.90e-01 | 0.0436 |
509 | ATP5F1C | GSM4909306 | Human | Breast | IDC | 9.97e-07 | 3.14e-01 | 0.1564 |
509 | ATP5F1C | GSM4909307 | Human | Breast | IDC | 8.39e-03 | 3.11e-01 | 0.1569 |
509 | ATP5F1C | GSM4909308 | Human | Breast | IDC | 2.09e-21 | 5.68e-01 | 0.158 |
509 | ATP5F1C | GSM4909311 | Human | Breast | IDC | 9.56e-15 | -2.02e-02 | 0.1534 |
509 | ATP5F1C | GSM4909312 | Human | Breast | IDC | 2.15e-07 | 3.37e-01 | 0.1552 |
509 | ATP5F1C | GSM4909315 | Human | Breast | IDC | 9.83e-22 | 6.42e-01 | 0.21 |
509 | ATP5F1C | GSM4909316 | Human | Breast | IDC | 1.03e-09 | 6.18e-01 | 0.21 |
509 | ATP5F1C | GSM4909317 | Human | Breast | IDC | 1.26e-04 | 2.68e-01 | 0.1355 |
509 | ATP5F1C | GSM4909318 | Human | Breast | IDC | 1.08e-04 | 5.75e-01 | 0.2031 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00092011 | Colorectum | SER | ribonucleoside triphosphate biosynthetic process | 30/2897 | 74/18723 | 1.76e-07 | 9.97e-06 | 30 |
GO:00091421 | Colorectum | SER | nucleoside triphosphate biosynthetic process | 32/2897 | 85/18723 | 5.16e-07 | 2.53e-05 | 32 |
GO:00091521 | Colorectum | SER | purine ribonucleotide biosynthetic process | 48/2897 | 169/18723 | 1.27e-05 | 4.01e-04 | 48 |
GO:00092601 | Colorectum | SER | ribonucleotide biosynthetic process | 49/2897 | 182/18723 | 4.85e-05 | 1.19e-03 | 49 |
GO:00463901 | Colorectum | SER | ribose phosphate biosynthetic process | 50/2897 | 190/18723 | 7.70e-05 | 1.72e-03 | 50 |
GO:00725221 | Colorectum | SER | purine-containing compound biosynthetic process | 51/2897 | 200/18723 | 1.55e-04 | 3.01e-03 | 51 |
GO:00061641 | Colorectum | SER | purine nucleotide biosynthetic process | 49/2897 | 191/18723 | 1.77e-04 | 3.30e-03 | 49 |
GO:00091651 | Colorectum | SER | nucleotide biosynthetic process | 58/2897 | 254/18723 | 1.21e-03 | 1.38e-02 | 58 |
GO:19012931 | Colorectum | SER | nucleoside phosphate biosynthetic process | 58/2897 | 256/18723 | 1.47e-03 | 1.59e-02 | 58 |
GO:00090602 | Colorectum | MSS | aerobic respiration | 98/3467 | 189/18723 | 3.35e-25 | 1.05e-21 | 98 |
GO:00060912 | Colorectum | MSS | generation of precursor metabolites and energy | 186/3467 | 490/18723 | 1.14e-24 | 2.15e-21 | 186 |
GO:00460342 | Colorectum | MSS | ATP metabolic process | 125/3467 | 277/18723 | 1.38e-24 | 2.15e-21 | 125 |
GO:00453332 | Colorectum | MSS | cellular respiration | 107/3467 | 230/18723 | 1.64e-22 | 2.05e-19 | 107 |
GO:00159802 | Colorectum | MSS | energy derivation by oxidation of organic compounds | 131/3467 | 318/18723 | 2.60e-21 | 2.70e-18 | 131 |
GO:00061192 | Colorectum | MSS | oxidative phosphorylation | 76/3467 | 141/18723 | 3.49e-21 | 3.11e-18 | 76 |
GO:00068392 | Colorectum | MSS | mitochondrial transport | 93/3467 | 254/18723 | 6.14e-12 | 9.82e-10 | 93 |
GO:00061632 | Colorectum | MSS | purine nucleotide metabolic process | 128/3467 | 396/18723 | 2.04e-11 | 3.02e-09 | 128 |
GO:00091502 | Colorectum | MSS | purine ribonucleotide metabolic process | 121/3467 | 368/18723 | 2.08e-11 | 3.02e-09 | 121 |
GO:00725212 | Colorectum | MSS | purine-containing compound metabolic process | 132/3467 | 416/18723 | 4.13e-11 | 4.86e-09 | 132 |
GO:00092592 | Colorectum | MSS | ribonucleotide metabolic process | 123/3467 | 385/18723 | 1.17e-10 | 1.20e-08 | 123 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |